Belite Bio (BLTE) Competitors $56.81 -0.35 (-0.61%) Closing price 04:00 PM EasternExtended Trading$59.71 +2.90 (+5.10%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLTE vs. RVMD, ELAN, LEGN, GRFS, TLX, TGTX, LNTH, NUVL, AXSM, and AKROShould you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Grifols (GRFS), Telix Pharmaceuticals (TLX), TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Belite Bio vs. Its Competitors Revolution Medicines Elanco Animal Health Legend Biotech Grifols Telix Pharmaceuticals TG Therapeutics Lantheus Nuvalent Axsome Therapeutics Akero Therapeutics Revolution Medicines (NASDAQ:RVMD) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership. Which has better valuation & earnings, RVMD or BLTE? Belite Bio has lower revenue, but higher earnings than Revolution Medicines. Belite Bio is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevolution Medicines$11.58M598.22-$600.09M-$4.00-9.30Belite BioN/AN/A-$36.14M-$1.36-41.77 Does the media refer more to RVMD or BLTE? In the previous week, Revolution Medicines had 12 more articles in the media than Belite Bio. MarketBeat recorded 14 mentions for Revolution Medicines and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.11 beat Revolution Medicines' score of 0.73 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, RVMD or BLTE? Revolution Medicines has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.5, meaning that its stock price is 250% less volatile than the S&P 500. Do analysts recommend RVMD or BLTE? Revolution Medicines currently has a consensus target price of $67.58, indicating a potential upside of 81.72%. Belite Bio has a consensus target price of $96.67, indicating a potential upside of 70.16%. Given Revolution Medicines' higher possible upside, research analysts plainly believe Revolution Medicines is more favorable than Belite Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals hold more shares of RVMD or BLTE? 94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is RVMD or BLTE more profitable? Belite Bio's return on equity of -32.07% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Revolution MedicinesN/A -37.06% -32.84% Belite Bio N/A -32.07%-30.91% SummaryRevolution Medicines beats Belite Bio on 7 of the 13 factors compared between the two stocks. Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLTE vs. The Competition Export to ExcelMetricBelite BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.82B$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-41.7721.3126.1719.90Price / SalesN/A278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book12.047.518.055.38Net Income-$36.14M-$55.05M$3.15B$248.50M7 Day Performance-7.02%2.45%1.85%2.97%1 Month Performance-12.63%7.33%4.81%6.02%1 Year Performance24.86%5.38%34.86%20.39% Belite Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLTEBelite Bio2.5018 of 5 stars$56.81-0.6%$96.67+70.2%+24.7%$1.82BN/A-41.7710High Trading VolumeRVMDRevolution Medicines4.4934 of 5 stars$40.04+1.0%$67.08+67.5%-4.9%$7.39B$11.58M-10.01250Analyst RevisionELANElanco Animal Health2.3246 of 5 stars$13.36-0.7%$15.17+13.5%+2.5%$6.68B$4.44B18.059,000Analyst ForecastLEGNLegend Biotech3.34 of 5 stars$33.85-0.4%$76.20+125.1%-21.1%$6.25B$627.24M-57.372,609Positive NewsAnalyst ForecastGRFSGrifols4.1298 of 5 stars$8.37-4.6%$10.30+23.1%+43.3%$6.03B$7.81B7.1523,822Analyst DowngradeTLXTelix PharmaceuticalsN/A$16.39-4.4%$22.00+34.2%N/A$5.80B$516.72M0.00N/AGap DownHigh Trading VolumeTGTXTG Therapeutics3.7651 of 5 stars$36.56+1.5%$40.80+11.6%+95.0%$5.72B$329M152.33290LNTHLantheus4.4467 of 5 stars$80.81+2.0%$130.50+61.5%-0.7%$5.48B$1.53B22.96700Positive NewsNUVLNuvalent3.7277 of 5 stars$75.98+1.3%$115.50+52.0%+3.3%$5.39BN/A-17.3140Analyst UpgradeInsider TradeAXSMAxsome Therapeutics4.6769 of 5 stars$101.65+1.0%$172.33+69.5%+27.1%$4.96B$385.69M-17.62380Analyst RevisionAKROAkero Therapeutics3.6224 of 5 stars$54.03-0.3%$82.50+52.7%+122.0%$4.32BN/A-27.7130 Related Companies and Tools Related Companies RVMD Alternatives ELAN Alternatives LEGN Alternatives GRFS Alternatives TLX Alternatives TGTX Alternatives LNTH Alternatives NUVL Alternatives AXSM Alternatives AKRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLTE) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
